Canada Gazette, Part I, Volume 156, Number 51: GOVERNMENT NOTICES

December 17, 2022

DEPARTMENT OF HEALTH

CANADIAN ENVIRONMENTAL PROTECTION ACT, 1999

Proposed guidance on sampling and mitigation measures for controlling corrosion

Pursuant to subsection 55(3) of the Canadian Environmental Protection Act, 1999, the Minister of Health hereby gives notice of a proposed guidance on sampling and mitigation measures for controlling corrosion. The proposed guidance document is available for public comment from December 17, 2022, to February 15, 2023, on the Health Canada webpage for public consultations. Any person may, within 60 days after publication of this notice, file with the Minister of Health written comments on the proposed document. Comments should be submitted by email to water-eau@hc-sc.gc.ca.

December 17, 2022

Greg Carreau
Director General
Safe Environments Directorate
On behalf of the Minister of Health

ANNEX
Executive summary

Corrosion is a common issue in Canadian drinking water supplies. Corrosion is the deterioration of a material, usually a metal, that results from a reaction with its environment. In drinking water distribution systems, materials that could be affected by corrosion and release increased amounts of contaminants (specifically metals, such as lead) include metal pipes (e.g. lead service lines) and fittings. There are no direct health effects linked to corrosion in distribution systems. However, corrosion may cause the release of contaminants that would be a concern for the health of Canadians. The main contaminant of concern is lead, for which the key health endpoint of concern is the reduction in intelligence quotient (IQ) scores in children. Lead is used as the trigger to initiate corrosion control programs to control or mitigate its release. Corrosion control treatment can effectively minimize lead concentrations at the point of consumption. However, when water is supplied through a lead service line, treatment alone may not be sufficient to reduce lead to concentrations below Health Canada’s maximum allowable concentration (MAC) of 0,005 mg/L (5 µg/L). Therefore, the removal of the full lead service line is likely the most effective and most permanent solution.

In this document, “corrosion” refers to the internal corrosion of the distribution system and not external corrosion of the infrastructure. In addition, “corrosion control” refers to the action of controlling or mitigating the release of metals, primarily lead, that results from the corrosion of materials in drinking water distribution systems. Information on components of a corrosion control program is provided; however, detailed operational aspects, such as developing a corrosion plan or removal of lead service lines, are outside the scope of this document. Resources for these components are listed in Appendix G. Microbiologically influenced corrosion is briefly discussed but detailed information is beyond the scope of this document.

Although corrosion itself cannot readily be measured by any single, reliable method, the levels of lead at a consumer’s tap can be used as an indication of corrosion. Corrosion control programs will vary depending on the responsible authority. They can range from extensive, system-wide programs implemented by the water utility to localized programs implemented by a building owner to ensure a safe and healthy environment for the occupants of residential and non-residential buildings.

This guidance document was prepared in collaboration with the Federal-Provincial-Territorial Committee on Drinking Water and assesses all available information on corrosion control in the context of drinking water quality and safety.

Assessment

The intent of this document is to provide responsible authorities, such as municipalities and water suppliers, with guidance on assessing corrosion and implementing corrosion control measures for distribution systems in residential settings to minimize exposure to lead. It also provides sampling protocols and corrective measures for multi-dwelling buildings, schools, daycare facilities and office buildings, for those authorities, such as school boards, building owners or employers, that are responsible for the health and safety of the occupants of such buildings.

This document outlines the steps that should be taken to reduce population exposure to lead, which may also reduce the consumer’s exposure to other corrosion-related contaminants, such as copper. Concerns related to other contaminants whose concentrations may be affected by corrosion, such as iron, are also briefly discussed.

This guidance is intended to complement the information provided in the guideline technical document of the guidelines for Canadian drinking water quality for lead.

DEPARTMENT OF HEALTH

DEPARTMENT OF HEALTH ACT

Notice of annual increase of Drug Master Files and Certificate of Pharmaceutical Product fees of the Department of Health

Notice is hereby given that the Minister of Health, under the Ministerial Authority to Enter into Contract, updates the fees that are payable for the provision of Drug Master Files and Certificate of Pharmaceutical Product services by 2%.

The current fees and the fees updated as of April 1, 2023, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or cro-brc@hc-sc.gc.ca (email).

Annual increase of Drug Master Files and Certificate of Pharmaceutical Product fees
Services Fee as of April 1, 2022 Fee as of April 1, 2023
Certificate of Pharmaceutical Product (or a supplemental copy of a Certificate of Pharmaceutical Product) $96 $98
New Master Files (file registration) $1,324 $1,351
Drug Master Files — letter of access $188 $192
Drug Master Files — update $575 $587

DEPARTMENT OF HEALTH

FINANCIAL ADMINISTRATION ACT

Notice of annual adjustment of fees for dealer’s licences

Notice is hereby given, under section 19.2 of the Financial Administration Act, that in keeping with section 4 of the Fees in Respect of Dealer’s Licences Regulations, the fee for dealer’s licences: human drugs will increase by the annual 2% amount, rounded up to the nearest dollar. Under subsection 17(1) of the Service Fees Act (a fee is adjusted in each fiscal year — on the anniversary of a date that is selected by the responsible authority with respect to the fee before the first adjustment — by the percentage change over 12 months in the April All-items Consumer Price Index [CPI] for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year), the dealer’s licence: veterinary drugs (as per the Licensed Dealers for Controlled Drugs and Narcotics (Veterinary Use) Fees Regulations) will be adjusted by the CPI. Health Canada has chosen April 1 as the anniversary date. The CPI for this year is 6.8%.

The current fees and the fees updated as of April 1, 2023, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or cro-brc@hc-sc.gc.ca (email).

Annual adjustment of fees for dealer’s licences
Type of licence Fee as of April 1, 2022 Fee as of April 1, 2023
Dealer’s licence (human drugs) $5,613 $5,726
Dealer’s licence (veterinary drugs) $1,882.52 $2,010.53

DEPARTMENT OF HEALTH

FOOD AND DRUGS ACT

Notice of annual adjustment of the Fees in Respect of Drugs and Medical Devices Order

Notice is hereby given, under subsection 30.61(1) of the Food and Drugs Act, that in keeping with section 4.1 of the 2020 Fees in Respect of Drugs and Medical Devices Order, every fee outlined in the Order is to be adjusted annually based on the Consumer Price Index (CPI). The CPI is calculated based on the percentage change over 12 months in the April All-items CPI for Canada, as published by Statistics Canada under the Statistics Act, for the previous fiscal year. The CPI for this year is 6.8%.

Most fees in the Fees in Respect of Drugs and Medical Devices Order are currently being phased in over four or seven years.

The current fees and the fees updated as of April 1, 2023, are listed below.

Any inquiries or comments about the updated fees can be directed to Etienne Ouimette, Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or cro-brc@hc-sc.gc.ca (email).

Human Drug Submission Review

Part 2 — Drugs

Table 1: Fees for examination of a submission — drugs for human use (Schedule 1)
Section in the Fees in Respect of Drugs and Medical Devices Order Submission class Fee as of April 1, 2022 Fee as of April 1, 2023
Section 9 New active substance $490,666 $565,465
  Clinical or non-clinical data and chemistry and manufacturing data $253,015 $292,806
  Clinical or non-clinical data only $104,339 $117,080
  Comparative studies $59,708 $65,985
  Chemistry and manufacturing data only $34,831 $40,597
  Clinical or non-clinical data only, in support of safety updates to the labelling $20,064 $21,429
  Labelling only $4,997 $5,901
  Labelling only (generic drugs) $2,075 $2,217
  Administrative submission $698 $933
  Disinfectant — full review $9,211 $12,297
  Labelling only (disinfectants) $2,588 $2,764
  Drug identification number application — labelling standard $1,668 $1,782
Table 2: Fees for examination of a submission — drugs for veterinary use only (Schedule 2)
Section in the Fees in Respect of Drugs and Medical Devices Order Type of submission Component Fee as of April 1, 2022 Fee as of April 1, 2023
Section 21 Application for drug identification number (DIN) Information, other than that referred to in the item below, to support an application for a drug identification number, including the submission of labelling material for a second review, if required $1,483 $1,891
    Published references or other data $1,031 $1,314
    Documentation to support a change of manufacturer, a change to the name of a manufacturer or a change to the brand name of a drug $516 $658
  Notification — veterinary health product Information contained in a notification filed under subsection C.01.615(1) of the Food and Drug Regulations in respect of a veterinary health product $503 $538
  New drug submissions (NDS) Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in one animal species (in the case of an antiparasitic drug, several indications in one food animal species) $32,855 $41,917
    Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species $19,903 $25,392
    Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species $47,780 $60,961
    Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species $64,700 $82,548
    Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration $5,965 $7,610
    Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength $989 $1,261
    For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $44,800 $57,158
    For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $59,724 $76,201
    For food-producing animals, residue depletion studies to establish a withdrawal period for an additional dosage form, dosage or route of administration $5,965 $7,610
    For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in an additional species $29,853 $38,088
    Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug $9,953 $12,697
    Chemistry and manufacturing data to support one strength of a single dosage form $9,953 $12,697
    Chemistry and manufacturing data to support an additional strength of a single dosage form submitted at the same time as the item above $4,978 $6,350
    Documentation to support a change of manufacturer $516 $658
  Supplement to a new drug submission (SNDS) Efficacy data to support an
additional indication in one animal species		 $25,886 $33,026
    Efficacy and safety data (in the intended species) to support a single route of administration and dosage form for an antiparasitic drug in one non-food animal species $19,903 $25,392
    Efficacy and safety data (in the intended species) to support an indication in another animal species $32,855 $41,917
    Efficacy and safety data (in the intended species) to support a single route of administration, dosage form and indication in two animal species, or a single route of administration and dosage form and two indications in one animal species $47,780 $60,961
    Efficacy and safety data (in the intended species) to support a growth promotion or production enhancement indication in one animal species $64,700 $82,548
    Efficacy and safety data (in the intended species) to support the concurrent use of two drugs approved for the same animal species $15,915 $20,305
    Comparative (pharmacodynamic, clinical or bioavailability) data to support an additional route of administration $5,965 $7,610
    Comparative (pharmacodynamic, clinical or bioavailability) data to support each additional strength $989 $1,261
    For food-producing animals, residue depletion studies to establish a new withdrawal period for a change in the dosage or route of administration of an approved dosage form in one species $5,965 $7,610
    For food-producing animals, metabolism and residue depletion studies to establish a maximum residue limit and a withdrawal period for a single dosage and route of administration of an approved dosage form in an additional species $29,853 $38,088
    For food-producing animals, toxicity studies to support a change of an established acceptable daily intake, a maximum residue limit and a withdrawal period $14,927 $19,045
    For the concurrent use of two drugs in a species of food-producing animals, residue depletion studies to determine if an extension to existing withdrawal periods is required $11,946 $15,243
    Chemistry and manufacturing data to support a change in the source of a medicinal ingredient or its manufacturing process $9,953 $12,697
    Chemistry and manufacturing data to support a change in formulation or dosage form $4,978 $6,350
    Chemistry and manufacturing data to support a change in the packaging or sterilization process $3,972 $5,065
    Chemistry and manufacturing data to support an extension of the expiry date $2,985 $3,807
    Chemistry and manufacturing data to support the concurrent use of two drugs $2,985 $3,807
    Chemistry and manufacturing data to support a change in the manufacturing site for parenteral dosage form $989 $1,261
    Documentation to support a change to the brand name of a drug $516 $658
  Abbreviated new drug submission (ANDS) or supplement to an abbreviated new drug submission (SANDS) Comparative (pharmacodynamic, clinical or bioavailability) data to support a single route of administration and dosage form $5,965 $7,610
    For food-producing animals, residue depletion studies to confirm that the withdrawal periods for each species fall within the conditions of use for the Canadian reference product $5,965 $7,610
    Chemistry and manufacturing data for a non-compendial medicinal ingredient of a drug $9,953 $12,697
    Chemistry and manufacturing data to support a single dosage form $9,953 $12,697
    Documentation to support (a) a change of manufacturer, in the case of an abbreviated new drug submission; or (b) a change to the brand name of a drug, in the case of a supplement to an abbreviated new drug submission $516 $658
  Preclinical submission Efficacy and safety data (in the intended species) and protocol to support the conduct of clinical studies relative to a single dosage form, route of administration and indication in one species $9,953 $12,697
    Efficacy data and protocol to support the conduct of clinical studies relative to a single route of administration and indication with a dosage form for which a notice of compliance has been issued for use in the species to be treated $7,959 $10,153
    For food-producing animals, toxicity, metabolism and residue depletion studies to establish a temporary acceptable daily intake, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $29,853 $38,088
    For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $44,800 $57,158
    For food-producing animals, toxicity, metabolism and residue depletion studies to establish an acceptable daily intake with a safety factor of less than 1 000, a maximum residue limit and a withdrawal period for a single dosage form, dosage and route of administration in one species $59,724 $76,201
    For food-producing animals (once an acceptable daily intake with a safety factor of 1 000 or less has been established), metabolism studies to establish a withdrawal period for a single dosage form, dosage and route of administration in an additional species $14,927 $19,045
    Chemistry and manufacturing data to support a single dosage form containing a non-compendial medicinal ingredient $9,953 $12,697
    Chemistry and manufacturing data to support a single dosage form containing a compendial medicinal ingredient $4,978 $6,350
  Sale of new drug for emergency treatment Information and material to support the sale of a new drug to be used in
the emergency treatment of a
non-food-producing animal		 $53 $57
    Information and material to support the sale of a new drug to be used in the emergency treatment of a food-producing animal $106 $114
  Experimental studies certificate Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a non-food-producing animal $1,013 $1,082
    Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for
a drug to be administered to a
non-food-producing animal		 $507 $542
    Information and material to support the issuance of an experimental studies certificate for a drug to be administered to a food-producing animal $3,054 $3,262
    Information and material to support the issuance of an experimental studies certificate whose protocol is the same as that of a previously authorized experimental studies certificate for a drug to be administered to a food-producing animal $507 $542
  Notifiable change or protocol review Information and material to support an application for a notifiable change $2,674 $3,413
    A protocol that is filed with the Minister and may support a new drug submission, an abbreviated new drug submission, a supplement to a new drug submission or abbreviated new drug submission, a preclinical submission or information and material that is filed for the purpose of obtaining an experimental studies certificate $2,674 $3,413
Table 3: Fees for examination of an application for an establishment licence — drugs for human use (Schedule 3)
Section in the Fees in Respect of Drugs and Medical Devices Order Activity Fee as of April 1, 2022 Fee as of April 1, 2023
Sections 33 and 41 Fabrication — sterile dosage form $43,171 $46,221
Sections 34 and 42 Importation $31,688 $35,688
Sections 35 and 43 Fabrication — non-sterile dosage form $30,677 $34,266
Sections 36 and 44 Distribution $15,691 $18,251
Sections 37 and 45 Wholesaling $7,962 $10,630
Sections 38 and 46 Packaging/labelling $6,225 $6,681
Sections 39 and 47 Testing $4,129 $5,514
Section 40 Foreign site (each) $949 $1,014
Table 4: Fees for examination of an application for an establishment licence — drugs for veterinary use only (Schedule 4)
Section in the Fees in Respect of Drugs and Medical Devices Order Activity Fee as of April 1, 2022 Fee as of April 1, 2023
Sections 33 and 41 Fabrication — sterile dosage form $42,080 $45,262
Sections 34 and 42 Importation $17,278 $23,066
Sections 35 and 43 Fabrication — non-sterile dosage form $14,161 $18,905
Sections 36 and 44 Distribution $7,797 $10,409
Sections 37 and 45 Wholesaling $3,117 $4,161
Sections 38 and 46 Packaging/labelling $6,255 $6,681
Sections 39 and 47 Testing $2,121 $2,833
Section 40 Foreign site (each) $949 $1,014
Table 5: Fees for right to sell drugs for human use (Schedule 6)
Section in the Fees in Respect of Drugs and Medical Devices Order Type of drug Fee as of April 1, 2022 Fee as of April 1, 2023
Section 52 Disinfectant $1,449 $1,613
Non-prescription $2,500 $3,109
Drug other than one referred to in item 1 or 2 (above) $4,211 $5,158
Table 6: Fees for right to sell drugs for veterinary use only (Schedule 7)
Section in the Fees in Respect of Drugs and Medical Devices Order Type of drug Fee as of April 1, 2022 Fee as of April 1, 2023
Section 56 Veterinary drug $437 $528

Part 3 — Medical devices

Table 7: Fees for examination of an application for a medical device licence (Schedule 8)
Section in the Fees in Respect of Drugs and Medical Devices Order Category Fee as of April 1, 2022 Fee as of April 1, 2023
Section 60 Applications for Class II licence $522 $589
  Applications for Class II licence amendment $282 $302
  Applications for Class III licence $10,679 $12,987
  Applications for Class III licence (near patient) $20,723 $27,666
  Applications for Class III licence amendment — changes in manufacturing $3,070 $4,098
  Applications for Class III licence amendment — significant changes not related to manufacturing $8,780 $10,425
  Applications for Class IV licence $25,955 $28,165
  Applications for Class IV licence amendment — changes in manufacturing $3,070 $4,098
  Applications for Class IV licence amendment — significant changes not related to manufacturing $12,128 $14,902
  Applications for Class II, III or IV licence or licence amendment — private label medical device $152 $163
Table 8: Fees for examination of an application for an establishment licence — medical devices
Section in the Fees in Respect of Drugs and Medical Devices Order Fee category Fee as of April 1, 2022 Fee as of April 1, 2023
Section 71 Medical device $4,737 $5,060
Table 9: Fees for right to sell licensed Class II, III or IV medical devices
Section in the Fees in Respect of Drugs and Medical Devices Order Fee category Fee as of April 1, 2022 Fee as of April 1, 2023
Section 77 Medical device $394 $421

DEPARTMENT OF HEALTH

PATENT ACT

Notice of annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations

Notice is hereby given, that in keeping with subsection 9(1) of the Certificate of Supplementary Protection Regulations, the fee will increase by the annual 2% amount, rounded up to the nearest dollar.

The current fee and the fee updated as of April 1, 2023, are listed below.

Any inquiries or comments about the updated fee can be directed to Etienne Ouimette, Director General, Resource Management and Operations Directorate, Health Products and Food Branch, 613‑957‑6690 (telephone) or cro-brc@hc-sc.gc.ca (email).

Annual increase of fee pursuant to the Certificate of Supplementary Protection Regulations
Type of certificate Subsection in Certificate of Supplementary Protection Regulations Fee as of April 1, 2022 Fee as of April 1, 2023
Certificate of Supplementary Protection 9(1) $9,952 $10,152

DEPARTMENT OF INDUSTRY

OFFICE OF THE REGISTRAR GENERAL

Appointments

December 9, 2022

Rachida Lagmiri
Official Documents Registrar

PRIVY COUNCIL OFFICE

Appointment opportunities

We know that our country is stronger — and our government more effective — when decision-makers reflect Canada’s diversity. The Government of Canada has implemented an appointment process that is transparent and merit-based, strives for gender parity, and ensures that Indigenous peoples and minority groups are properly represented in positions of leadership. We continue to search for Canadians who reflect the values that we all embrace: inclusion, honesty, fiscal prudence, and generosity of spirit. Together, we will build a government as diverse as Canada.

We are equally committed to providing a healthy workplace that supports one’s dignity, self-esteem and the ability to work to one’s full potential. With this in mind, all appointees will be expected to take steps to promote and maintain a healthy, respectful and harassment-free work environment.

The Government of Canada is currently seeking applications from diverse and talented Canadians from across the country who are interested in the following positions.

Current opportunities

The following opportunities for appointments to Governor in Council positions are currently open for applications. Every opportunity is open for a minimum of two weeks from the date of posting on the Governor in Council appointments website.

Governor in Council appointment opportunities
Position Organization Closing date
Director Asia-Pacific Foundation of Canada  
Director Bank of Canada  
Director Business Development Bank of Canada  
Chairperson Canada Agricultural Review Tribunal  
Director Canada Council for the Arts  
Director Canada Deposit Insurance Corporation  
Director Canada Development Investment Corporation  
Director Canada Foundation for Sustainable Development Technology  
President Canada Lands Company Limited  
Director Canada Post Corporation  
Director Canada Revenue Agency  
Member Canada–Nova Scotia Offshore Petroleum Board  
Chairperson Canadian Air Transport Security Authority  
Chief Executive Officer Canadian Air Transport Security Authority  
Director Canadian Commercial Corporation  
Member Canadian Cultural Property Export Review Board  
Director Canada Energy Regulator  
Chairperson Canadian High Arctic Research Station  
Member Canadian High Arctic Research Station  
Vice-Chairperson Canadian High Arctic Research Station  
Chief Commissioner Canadian Human Rights Commission  
Pay Equity Commissioner Canadian Human Rights Commission  
Member Canadian Human Rights Tribunal  
Member Canadian Institutes of Health Research  
Secretary Canadian Intergovernmental Conference Secretariat  
Trustee Canadian Museum of Immigration at Pier 21  
Chairperson Canadian Museum of Nature  
Chairperson Canadian Radio-television and Telecommunications Commission  
Vice-Chairperson Canadian Radio-television and Telecommunications Commission  
Member Canadian Statistics Advisory Council  
Member Canadian Transportation Agency  
Special Representative on Combatting Islamophobia Department of Canadian Heritage  
Chairperson Export Development Canada  
Director Export Development Canada  
President Farm Credit Canada  
Director First Nations Financial Management Board  
Deputy Administrator Fund for Railway Accidents Involving Designated Goods  
Member Historic Sites and Monuments Board of Canada  
Member Immigration and Refugee Board  
Commissioner International Commission on the Conservation of Atlantic Tunas  
President International Development Research Centre  
Commissioner International Joint Commission  
Director Invest in Canada Hub  
Commissioner Law Commission of Canada  
President Law Commission of Canada  
Chairperson Military Grievances External Review Committee  
Vice-Chairperson Military Grievances External Review Committee  
Chairperson National Arts Centre Corporation  
Chairperson National Capital Commission  
Member National Capital Commission  
Member National Farm Products Council  
Vice-Chairperson National Farm Products Council  
Director National Gallery of Canada  
Member Net-Zero Advisory Body  
Canadian Representative North Atlantic Salmon Conservation Organization  
Canadian Representative North Pacific Anadromous Fish Commission  
Public Sector Integrity Commissioner Office of the Public Sector Integrity Commissioner  
Member Pacific Pilotage Authority  
Chairperson Patented Medicine Prices Review Board  
Director Public Sector Pension Investment Board  
Commissioner Public Service Commission  
Chairperson Royal Canadian Mounted Police Management Advisory Board  
Member Royal Canadian Mounted Police Management Advisory Board  
Vice-Chairperson Royal Canadian Mounted Police Management Advisory Board  
Deputy Administrator Ship-source Oil Pollution Fund  
Deputy Registrar Supreme Court of Canada  
Executive Director Telefilm Canada  
Chief Executive Officer VIA Rail Canada Inc.  

TREASURY BOARD SECRETARIAT

Targeted Regulatory Reviews — Request for stakeholder comments

Effective regulations promote social and economic well-being, protect health and safety, and foster innovation and a competitive business environment. In recent years, the Government of Canada has undertaken a number of initiatives to modernize the Canadian regulatory system and improve its performance for Canadians and businesses. Among those initiatives are the targeted Regulatory Reviews, which examine regulation and regulatory practices to identify bottlenecks and opportunities to support economic growth and innovation, while continuing to prioritize health, safety, security, and environmental responsibilities.

Background

In December 2019, the Minister of Fisheries, Oceans and the Canadian Coast Guard was mandated to lead the development of a comprehensive Blue Economy Strategy (BES). The BES will outline Canada’s vision for its ocean-related sectors and help guide future federal government actions and investments that enable long-term sustainable growth, especially for coastal communities.

From February 8 to June 15, 2021, a public engagement process occurred, through which the Department of Fisheries and Oceans (DFO or the Department) received input based on a series of questions in response to the Blue Economy Strategy Engagement Paper. More than 1 600 Canadians shared their ideas and perspectives on how Canada should develop its BES.

On March 11, 2022, Minister Joyce Murray released What We Heard: Engaging on Canada’s Blue Economy Strategy, which provides a detailed summary of feedback received during the BES engagement process. Throughout the engagement process, there was a general consensus from Canadians on a desire to foster a blue economy that provides sustainable growth opportunities and enhances the participation of underrepresented groups to promote equity, address gaps in labour market skills, and drive innovation in the ocean economy.

Purpose for engagement call out

Under the leadership of DFO, and with the support of the Treasury Board of Canada Secretariat (TBS), the third round of Targeted Regulatory Reviews will include a review focused on the blue economy. The Blue Economy Regulatory Review will examine the role of regulation as a driver of ocean innovation, identify regulatory and administrative barriers to environmentally sustainable growth, and facilitate the development of agile regulations to address the concerns of future-oriented ocean industries.

The feedback of Canadians to date has resulted in the identification and prioritization of five specific theme areas for which DFO is seeking additional insight at this time. The proposed blue economy themes, guiding questions, and instructions for submissions are summarized below.

DFO will continue to make use of input submitted to date. Canadians interested in re-emphasizing previous input can simply refer to their past submission using the online platform referenced below. There is no need to resubmit input already submitted.

The Blue Economy Regulatory Review will focus on the following five themes:

Information about specific issues and questions on which DFO is seeking feedback is available on the Blue Economy Regulatory Review project page. While the Department currently prioritizes these five themes, contributors will also have an ability to provide insights about other topics on the online platform.

How to participate

DFO is seeking feedback through the Blue Economy Regulatory Review project using Let’s Talk Federal Regulations, the online engagement platform being piloted by TBS.

Canadians can visit the Blue Economy Regulatory Review project web page and share their views by March 17, 2023.

How input will be used

Responses received from this consultation will be used to inform the Blue Economy Regulatory Roadmap. Regulatory roadmaps lay out plans to advance regulatory modernization in support of economic growth and innovation.

The Government of Canada will provide a summary of the responses received in its public documents. In addition, all comments received will be made public on the Open Data portal following the consultation.

Sharing views using this platform provides an opportunity to engage in conversation with others. However, contributors who would prefer to keep portions or all of their submission confidential, or would like their identity removed from comments prior to publication, are invited to email the Department at BlueEconomy-EconomieBleue@dfo-mpo.gc.ca.

For more information, please see the Let’s Talk Federal Regulations Privacy Policy and Terms of Use.